DelveInsight has launched a new report on Focal Segmental Glomerulosclerosis Pipeline Insight, 2020
“Focal Segmental Glomerulosclerosis (FSGS) Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Focal Segmental Glomerulosclerosis (FSGS) market. A detailed picture of the Focal Segmental Glomerulosclerosis (FSGS) pipeline landscape is provided, which includes the disease overview and Focal Segmental Glomerulosclerosis (FSGS) treatment guidelines. The assessment part of the report embraces in-depth Focal Segmental Glomerulosclerosis (FSGS) commercial assessment and clinical assessment of the Focal Segmental Glomerulosclerosis (FSGS) pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Focal Segmental Glomerulosclerosis (FSGS) collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
The report provides insights into:
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third-party sources, etc.
Analytical Perspective
This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, licensing, and acquisition deal value trends. The report also covers company-company collaborations (licensing/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form in a detailed manner.
The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.
Report Highlights:-
Report Key facts:-
1. Age plays important role in the prevalence of FSGS. As per DelveInsight estimates, there were 4,306 cases of children with FSGS, while adults contribute 8,613 cases of FSGS in 2017 for Germany.
2. In 2017, there were 45,852 prevalent cases of FSGS in males and 34,731 cases in females and as per analyst assessments, the overall cases of FSGS in both the genders is subjected to increase in the coming years in 7MM.
“According to DelveInsight’s analysis, Male cases of FSGS are more prominent in comparison to Female”
Key companies are working on FSGS are given below:-
1. Retrophin Pharma Co
2. Dimerix Pharma Co.
3.Aurinia Pharmaceuticals.
Name of drugs covered that are given below:-
1. Sparsentan2. DMX-2003. Voclosporin
Table of Contents
1. Report Introduction
2. Focal Segmental Glomerulosclerosis (FSGS)
2.1. Overview
2.2. History
2.3. Focal Segmental Glomerulosclerosis (FSGS) Symptoms
2.4. Causes
2.5.Pathophysiology
2.6. Focal Segmental Glomerulosclerosis (FSGS) Diagnosis
2.6.1. Diagnostic Guidelines
3. Focal Segmental Glomerulosclerosis (FSGS) Current Treatment Patterns
3.1. Focal Segmental Glomerulosclerosis (FSGS) Treatment Guidelines
4. Focal Segmental Glomerulosclerosis (FSGS) – DelveInsight’s Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Focal Segmental Glomerulosclerosis (FSGS) companies collaborations, Licensing, Acquisition -Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Focal Segmental Glomerulosclerosis (FSGS) Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis
4.1.2.3. Focal Segmental Glomerulosclerosis (FSGS) Acquisition Analysis
5. Therapeutic Assessment
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Phase of Development
5.1.2. Assessment by Product Type (Mono / Combination)
5.1.2.1. Assessment by Stage and Product Type
5.1.3. Assessment by Route of Administration
5.1.3.1. Assessment by Stage and Route of Administration
5.1.4. Assessment by Molecule Type
5.1.4.1. Assessment by Stage and Molecule Type
5.1.5. Assessment by MOA
5.1.5.1. Assessment by Stage and MOA
5.1.6. Assessment by Target
5.1.6.1. Assessment by Stage and Target
6. Focal Segmental Glomerulosclerosis (FSGS) Late Stage Products (Phase-III)
7. Focal Segmental Glomerulosclerosis (FSGS) Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Focal Segmental Glomerulosclerosis (FSGS) Discontinued Products
13. Focal Segmental Glomerulosclerosis (FSGS) Product Profiles
13.1. Drug Name: Company
13.1.1. Product Description
13.1.1.1. Product Overview
13.1.1.2. Mechanism of action
13.1.2. Research and Development
13.1.2.1. Clinical Studies
13.1.3. Product Development Activities
13.1.3.1. Collaboration
13.1.3.2. Agreements
13.1.3.3. Acquisition
13.1.3.4. Patent Detail
13.1.4. Tabulated Product Summary
13.1.4.1. General Description Table
Detailed information in the report?
14. Focal Segmental Glomerulosclerosis (FSGS) Key Companies
15. Focal Segmental Glomerulosclerosis (FSGS) Key Products
16. Dormant and Discontinued Products
16.1. Dormant Products
16.1.1. Reasons for being dormant
16.2. Discontinued Products
16.2.1. Reasons for the discontinuation
17. Focal Segmental Glomerulosclerosis (FSGS) Unmet Needs
18. Focal Segmental Glomerulosclerosis (FSGS) Future Perspectives
19. Focal Segmental Glomerulosclerosis (FSGS) Analyst Review
20. Appendix
21. Report Methodology
21.1. Secondary Research
21.2. Expert Panel Validation
22. About Delveinsight
Related Reports:-
1. Focal Segmental Glomerulosclerosis (FSGS)- Market Insight, Epidemiology and Market Forecast -2030
2. Focal Segmental Glomerulosclerosis (FSGS) – Epidemiology Forecast to 2030
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: +919650213330Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/